Detalhe da pesquisa
1.
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.
Proc Natl Acad Sci U S A
; 110(32): E2987-96, 2013 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-23882082
2.
PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition.
J Pathol
; 234(4): 502-13, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25074413
3.
Nonclinical evaluation of the serum pharmacodynamic biomarkers HGF and shed MET following dosing with the anti-MET monovalent monoclonal antibody onartuzumab.
Mol Cancer Ther
; 13(2): 540-52, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24258345
4.
Onartuzumab (MetMAb): using nonclinical pharmacokinetic and concentration-effect data to support clinical development.
Clin Cancer Res
; 19(18): 5068-78, 2013 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23894056
5.
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival.
Cancer Res
; 68(11): 4360-8, 2008 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18519697